ARCH Venture Partners IX Overage, L.P.
10% Owner · Lyell Immunopharma, Inc.
Every open-market stock purchase ARCH Venture Partners IX Overage, L.P. has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- LYELLyell Immunopharma, Inc.
One purchase totalling $12.5M at an average of $25.61 per share. See all insider buying in LYEL →
Avg price paid$25.61Latest price—Market capUnknown
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
Follow new qualifying clusters involving ARCH Venture Partners IX Overage, L.P. or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from ARCH Venture Partners IX Overage, L.P.'s Form 4 filings on SEC EDGAR (CIK 1723172) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.